Medtronic (MDT) plans to separate its diabetes business into a standalone company, The Wall Street Journal’s Jared S. Hopkins reports, citing people familiar with the matter. The new company, led by the head of Medtronic’s diabetes division Que Dallara, will have around 8,000 employees and be based in Northridge, California, according to the report, which adds that the separation is expected to be completed within 18 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic Stock (MDT) Looks Poorly on Diabetes Arm Spin Off Plans
- Notable companies reporting before tomorrow’s open
- Is Medtronic Stock (MDT) a Buy Ahead of Earnings?
- Options Volatility and Implied Earnings Moves This Week, May 19 – May 22, 2025
- Options Volatility and Implied Earnings Moves This Week, May 19 – May 23, 2025